CN101897717B - Chinese medicinal composition for treating diabetes and application - Google Patents
Chinese medicinal composition for treating diabetes and application Download PDFInfo
- Publication number
- CN101897717B CN101897717B CN2010101817967A CN201010181796A CN101897717B CN 101897717 B CN101897717 B CN 101897717B CN 2010101817967 A CN2010101817967 A CN 2010101817967A CN 201010181796 A CN201010181796 A CN 201010181796A CN 101897717 B CN101897717 B CN 101897717B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- chinese medicine
- diabetes
- lycium barbarum
- astragalus polysaccharides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a Chinese medicinal composition for effectively treating diabetes. The Chinese medicinal composition comprises the following components of lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharide in a weight ratio of 5.5-7.5:1.5-2.5:1. Simultaneously, the invention also provides the application of the Chinese medicinal composition. The Chinese medicinal composition and the application thereof belong to the field of pharmacy.
Description
Technical field
The present invention relates to Chinese medicine, particularly a kind of Chinese medicine composition that is used for the treatment of diabetes.The present invention simultaneously also provides the pharmaceutical applications of this Chinese medicine composition.The invention belongs to pharmaceutical field.
Background technology
Diabetes are metabolic diseases of a kind of multi-pathogenesis, are characterized in chronic hyperglycemia, follow because of insulin secretion and/or effect the defective sugar, fat and the protein metabolism disorder that cause.Diabetes are seriously spread unchecked at present, 2003, the whole world had 1.94 hundred million people to suffer from diabetes, and the age was not waited from 20 years old to 79 years old, may increase by 72% and reach 3.33 hundred million to this numeral in 2025, and about 80% case will be distributed in country in the poor industrial development.Point out in the report on October 12nd, 2004 " Chinese residents nutrition and Health Situation " that Ministry of Public Health, the Department of Science and Technology and State Statistics Bureau announce: China 18 years old and above resident's diabetes prevalence are 2.6%, and the impaired fasting glucose (IFG) rate is 1.9%.Estimate the existing number of patients more than 2,000 ten thousand of national diabetes, other has nearly 2,000 ten thousand people's impaired fasting glucose (IFG).The city prevalence is compared with diabetes sampling survey data in 1996 apparently higher than the rural area, the big city more than 20 years old diabetes prevalence by 4.6% rise to 6.4%, small and medium-sized cities rise to 3.9% by 3.4%.Diabetes are still serious public health problem of China.
The prevalence of diabetes is ascendant trend year by year.Diabetes are a kind of non-infectious chronic diseases, need control all the life.Because the human at present cause of disease and the pathogenesis to diabetes fully do not understood, and still lacks etiotropic effective treatment means.Emphasize the principle of early treatment, long-term treatment and Comprehensive Treatment at present.The target of treatment is blood glucose to be reached or near normal level, corrects metabolism disorder, eliminates diabetic symptom, prevents or delays complication, keeps health, work and learning capacity, ensures upgrowth and development of children, and life-saving reduces case fatality rate.Concrete measure gives medicine (oral antidiabetic, insulin) treatment based on treatment and the suitable physical training of keeping on a diet according to the different state of an illness.Be type 2 diabetes mellitus more than 90% in the diabetic, 70%～85% patient need use oral hypoglycemic drug therapy at the initial stage of a disease, only has 15%～30% patient to add the standard that exercise therapy reaches Satisfactory Control with simple diet.In afterwards 1～3 year of the latter, also need add mostly with the orally-taken blood sugar reducing medicine just can make glycemic control satisfied [Li Chunlin. the oral hypoglycemic drug therapy of diabetes. the medical officer people, 2004,47 (9): 544-547].
Medication of Diabetes Mellifus is divided insulinize, orally-taken blood sugar reducing western medicine and naturopathy.The world of medicine generally adopts diabetes treatment by western medicine at present, and clinical oral antidiabetic thing commonly used comprises sulfonylurea hypoglycemic agent, biguanides antidiabetic drug, alpha-glucosidase inhibitor, thiazolidinediones (glitazone) antidiabetic drug, non-sulfonylurea Drugs Promoting Insulin Secretion etc.The diabetes treatment by western medicine toxic and side effects is big.In recent years, American-European countries begins to pay close attention to natural plant extracts, wishes that this class nature thing is helpful to diabetics.
Summary of the invention
Technical problem to be solved by this invention provides a kind of medicine that has no side effect and diabetes are had effective therapeutical effect.
Contain lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides in the Chinese medicine composition that the invention provides the treatment diabetes, wherein the weight ratio of lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides is 5.5-7.5: 1.5-2.5: 1.
The most a kind of preferred, the weight ratio of lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides is 6: 2: 1 in the Chinese medicine composition provided by the invention.
Chinese medicine composition provided by the invention can also contain puerarin, and the weight ratio of lycium barbarum polysaccharide, dendrobium polysaccharide, astragalus polysaccharides and puerarin is 6: 2: 1: 1.
As the medicine of treatment diabetes, Chinese medicine composition provided by the invention can add the pharmaceutics acceptable auxiliary and make the pharmaceutics acceptable forms.In the present invention, term pharmaceutically suitable carrier or excipient are to obtain the approval of sanitary administration mechanism to be used for this purpose, and they are non-activities as pharmaceutical agents." pharmaceutical excipient handbook (A.Wade and P.J.Weller chief editor, second edition, American Pharmaceutical Association, Washington and pharmacy publishing house, london publishing, 1994) has been edited pharmaceutically suitable carrier and excipient.
Another technical problem to be solved by this invention is that Chinese medicine composition provided by the invention is in the purposes that is used for preparing the medicine for the treatment of diabetes.Wherein, described pharmaceutical composition contains lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides, and wherein the weight ratio of lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides is 5.5-7.5: 1.5-2.5: 1.
Lycium barbarum polysaccharide is one of main effective ingredient of Fructus Lycii, and astragalus polysaccharides is one of main active of the Radix Astragali, and modern age, pharmacological evaluation showed, lycium barbarum polysaccharide, astragalus polysaccharides and dendrobium polysaccharide all have blood sugar reducing function.Among the present invention, lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides are with 5.5-7.5: 1.5-2.5: 1 weight ratio is combined, and can work in coordination with the blood sugar lowering level, compares more with single medicine and can demonstrate useful blood sugar reducing function.Diseases such as puerarin is the most important effective ingredient of Chinese medicine Radix Puerariae, and traditional Chinese medical science Radix Puerariae commonly used is the expelling pathogenic wind from the body surface medicine, and be mainly used in and show the malaria fever without perspiration, have a headache stiffness of the nape and macule are not saturating.In pharmaceutical composition provided by the invention, add Radix Puerariae, can improve the blood sugar reducing function effect of medicine.Simultaneously, another beneficial effect effect of pharmaceutical composition provided by the invention is, the blood sugar level of the horizontal normal patient of not obvious blood sugar lowering, and this has good protective action for the normal condition of keeping blood sugar level.
The specific embodiment
Embodiment 1Chinese medicine composition is to the influence of normal mouse fasting glucose
Medication preparation: lycium barbarum polysaccharide, dendrobium polysaccharide, astragalus polysaccharides, and be mixed with the solution of 0.3g/ml with 6: 2: 1 ratio.
Laboratory animal: cleaning level mice, 18-22g, male and female half and half are provided by Hong Kong University's Experimental Animal Center.
Reagent: glipizide is mixed with 0.5mg/ml as positive controls reagent.
Test method: mice is divided into 5 groups at random by body weight: (1) model group, (2) compositions low dose group, dosage group in (3) compositions, (4) compositions high dose group, (5) positive controls, 10 every group, every group of male and female half and half, fasting 24hrs, gastric infusion.Every day organized dosage by model group feeding every day distilled water, compositions low dosage is 30mg/kg, and dosage group dosage is 90mg/kg in the compositions, and compositions high dose group dosage is 270mg/kg, and the positive controls dosage is 2.5mg/kg, administration in continuous 7 days.Survey the fasting blood sugar of administration in the time of 1,3 and 7 days, respectively at fasting 3h before the last administration, 1h eye socket venous plexus blood sampling after the administration, collect blood sample, 37 ℃ of water-baths, the centrifugal 10min of 2500r/min, get upper serum, glucose oxidase method is surveyed blood glucose, and record blood glucose meansigma methods is calculated blood glucose decline percentage rate.The results are shown in Table 1.
Date processing: experimental result with
Expression, date processing adopts the analysis of SPSS software statistics.
1,3,7 days empty stomaches of table 1. medicine normal mouse administration blood sugar influence (
N=10)
With respect to model group
*P＜0.05;
*P＜0.01
After the administration 1,3,7 days, the positive controls blood glucose value is compared obvious decline with model group, and the basic, normal, high dosage group of compositions blood glucose value is compared with model group and is not had significance to change, show that pharmaceutical composition provided by the invention does not make significant difference to the fasting glucose of normal mouse, illustrate that pharmaceutical composition provided by the invention does not significantly stimulate the insulin release action, the blood sugar level that can not cause low normal mouse reduces, with respect to the glipizide antidiabetic drug, Chinese medicine pharmaceutical composition provided by the invention has more safety.
Embodiment 2. medicines are to the influence of alloxan induced hyperglycemia mice fasting glucose
Medication preparation: lycium barbarum polysaccharide, dendrobium polysaccharide, astragalus polysaccharides, and be mixed with the solution of 0.3g/ml with 6: 2: 1 ratio.
Laboratory animal: alloxan induced hyperglycemia mice, 18-22g, male and female half and half are provided by Hong Kong University's Experimental Animal Center.
Reagent: glipizide is mixed with 0.5mg/ml as positive controls reagent.
Test method: mice is divided into 5 groups at random by body weight: (1) model group, (2) compositions low dose group, dosage group in (3) compositions, (4) compositions high dose group, (5) positive controls, 10 every group, every group of male and female half and half, fasting 24hrs, gastric infusion.Every day organized dosage by model group feeding every day distilled water, compositions low dosage is 30mg/kg, and dosage group dosage is 90mg/kg in the compositions, and compositions high dose group dosage is 270mg/kg, and the positive controls dosage is 2.5mg/kg, administration in continuous 7 days.Survey the fasting blood sugar of administration in the time of 1,3 and 7 days, respectively at fasting 3h before the last administration, 1h eye socket venous plexus blood sampling after the administration, collect blood sample, 37 ℃ of water-baths, the centrifugal 10min of 2500r/min, get upper serum, glucose oxidase method is surveyed blood glucose, and record blood glucose meansigma methods is calculated blood glucose decline percentage rate.The results are shown in Table 2,3,4.
Date processing: experimental result with
Expression, date processing adopts the analysis of SPSS software statistics.
Table 2. medicine to 1 day fasting glucose of alloxan induced hyperglycemia mice administration influence (
N=10)
With respect to model group
*P＜0.05;
*P＜0.01
Table 3. medicine to 3 days fasting glucose of alloxan induced hyperglycemia mice administration influence (
N=10)
With respect to model group
*P＜0.05;
*P＜0.01
Table 4. medicine to 7 days fasting glucose of alloxan induced hyperglycemia mice administration influence (
N=10)
Thin with respect to model
*P＜0.05;
*P＜0.01
Table 2,3 shows that pharmaceutical composition provided by the invention can obviously reduce the blood glucose value of alloxan induced hyperglycemia mice, and compares with matched group, and there were significant differences; The hypoglycemic activity and the positive controls of pharmaceutical composition provided by the invention are suitable.Table 4 shows that pharmaceutical composition provided by the invention can reduce the blood glucose value of alloxan induced hyperglycemia mice in various degree, and middle dosage compares with matched group with the high dose medicament group, has significant difference.This result of study shows that pharmaceutical composition provided by the invention has obvious reduction effect to the fasting blood sugar of alloxan induced hyperglycemia mice, shows that it may have the impaired β cell function of improvement or reduce the effect of body to insulin resistance.1 day, 3 days, 7 days blood glucose decline percentage rate basically identical of administration illustrates that pharmaceutical composition provided by the invention has stable reduction effect to the fasting glucose of alloxan induced hyperglycemia mice.Simultaneously, being administered once to detect drug effect, shows that drug treating time is fast.
Claims (6)
1. a Chinese medicine composition for the treatment of diabetes contains lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides, and the weight ratio of lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides is 5.5-7.5: 1.5-2.5: 1.
2. Chinese medicine composition according to claim 1 is characterized in that: the weight ratio of lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides is 6: 2: 1.
3. Chinese medicine composition according to claim 2 is characterized in that: also contain puerarin in the described Chinese medicine composition, the weight ratio of lycium barbarum polysaccharide, dendrobium polysaccharide, astragalus polysaccharides and puerarin is 6: 2: 1: 1.
4. Chinese medicine composition according to claim 1 is characterized in that: contain pharmaceutically suitable carrier or excipient in the described Chinese medicine composition.
As each described Chinese medicine composition of claim 1-4 in the purposes that is used for preparing the medicine for the treatment of diabetes.
6. purposes according to claim 5 is characterized in that: described pharmaceutical composition contains lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides, and the weight ratio of lycium barbarum polysaccharide, dendrobium polysaccharide and astragalus polysaccharides is 5.5-7.5: 1.5-2.5: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101817967A CN101897717B (en) | 2010-05-25 | 2010-05-25 | Chinese medicinal composition for treating diabetes and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101817967A CN101897717B (en) | 2010-05-25 | 2010-05-25 | Chinese medicinal composition for treating diabetes and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101897717A CN101897717A (en) | 2010-12-01 |
| CN101897717B true CN101897717B (en) | 2011-12-14 |
Family
ID=43223860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101817967A Expired - Fee Related CN101897717B (en) | 2010-05-25 | 2010-05-25 | Chinese medicinal composition for treating diabetes and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101897717B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104522462A (en) * | 2014-12-04 | 2015-04-22 | 陈扬 | Glossy ganoderma dendrobium candidum polysaccharide and preparation technology thereof |
| CN105053955A (en) * | 2015-08-14 | 2015-11-18 | 蚌埠市华东生物科技有限公司 | Blood-glucose-reducing sweetening agent without lingering bitterness |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326771A (en) * | 2001-06-08 | 2001-12-19 | 王显勇 | Medicine for curing diabetes |
| CN1636579A (en) * | 2003-03-25 | 2005-07-13 | 邓家刚 | Hypoglycemic Chinese medicine prepn and its production process |
| CN101579483A (en) * | 2009-06-08 | 2009-11-18 | 姚民秀 | Chinese medicine composition for treating diabetes and complication and preparation method thereof |
-
2010
- 2010-05-25 CN CN2010101817967A patent/CN101897717B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326771A (en) * | 2001-06-08 | 2001-12-19 | 王显勇 | Medicine for curing diabetes |
| CN1636579A (en) * | 2003-03-25 | 2005-07-13 | 邓家刚 | Hypoglycemic Chinese medicine prepn and its production process |
| CN101579483A (en) * | 2009-06-08 | 2009-11-18 | 姚民秀 | Chinese medicine composition for treating diabetes and complication and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 倪艳等.糖尿病常用中药多糖类成分降血糖作用的现代研究概述.《山西中医》.2008,第24卷(第5期),第54-55页第3.3.1、3.3.3和3.3.4部分. * |
| 孙晓辉.葛根素治疗糖尿病的作用机制研究.《中国优秀博士学位论文全文数据库》.2007,第61页第5.2节. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101897717A (en) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011499B (en) | Linaloe leaf extract, pharmaceutical and health care uses thereof | |
| CN101890040B (en) | Composition with anti-fatigue effect and application thereof | |
| CN102416148B (en) | Medicine for treating depression, and preparation method and application thereof | |
| CN101926865B (en) | Spina date seed depression-resolving and nerve-soothing composition and preparation method thereof | |
| CN103417846B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN101284050B (en) | Corydalis tuber water soluble part medicament and its preparation method and application | |
| CN102716135B (en) | Lupenone prevents in preparation or treats the application in the product of diabetes | |
| CN101897717B (en) | Chinese medicinal composition for treating diabetes and application | |
| CN101926815A (en) | Paeoniflorin and glycyrrhetinic acid composition and preparation method and application thereof | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN101406642B (en) | Antihypelipidemic compound formulation | |
| CN104644734A (en) | Drug for treating type II diabetes and complications thereof | |
| CN104546987A (en) | Application of gynostemma pentaphyllum total saponins to prevention and cure of hyperuricemia | |
| CN101120969A (en) | Medicine for treating diabetes and its complications and preparing method thereof | |
| CN104042928A (en) | Pharmaceutical composition for treating diabetes and its preparation method and use | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN103656161B (en) | A kind of Chinese medicine composition and its production and use | |
| CN1575803A (en) | Application method of Aloe vera L. extract in preventing and curing diabetes | |
| CN101879214B (en) | Chinese medicinal composition for treating bronchial asthma and preparation method thereof | |
| CN102716260A (en) | Medicine for fast improving sperm quality and sexual function | |
| CN101618157B (en) | Medicine composition for treating autumn-dryness cold and preparation method thereof | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| CN1481796A (en) | Medication for adiposity | |
| CN102526243A (en) | Traditional Chinese medicine combination for clearing heat and tonifying qi and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111214 Termination date: 20130525 |